Nothing Special   »   [go: up one dir, main page]

GT200500007A - [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia. - Google Patents

[1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.

Info

Publication number
GT200500007A
GT200500007A GT200500007A GT200500007A GT200500007A GT 200500007 A GT200500007 A GT 200500007A GT 200500007 A GT200500007 A GT 200500007A GT 200500007 A GT200500007 A GT 200500007A GT 200500007 A GT200500007 A GT 200500007A
Authority
GT
Guatemala
Prior art keywords
treatment
related compounds
chichophrenia
naftiridin
waves
Prior art date
Application number
GT200500007A
Other languages
English (en)
Inventor
Jerry Clark
Jamie Davis
David Favor
Lorraine Fay
Llod Franklin
Kevin Heneger
Douglas Johnson
Brian Nichelson
Ligong Ou
Joseph Thomas Repine
Michael Walters
Andrew David White
Zhijian Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200500007A publication Critical patent/GT200500007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ESTA INVENCION SE REFIERE A [1,8]NAFTIRIDIN2ONAS Y A COMPUESTOS RELACIONADOS, A METODOS PARA FABRICAR TALES COMPUESTOS, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SU USO PARA EL TRATAMIENTO DE LAS ESQUIZOFRENIA Y OTROS TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL (SNC).
GT200500007A 2003-08-22 2005-01-13 [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia. GT200500007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49737003P 2003-08-22 2003-08-22
US10/900,210 US7160888B2 (en) 2003-08-22 2004-07-28 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
GT200500007A true GT200500007A (es) 2005-10-24

Family

ID=34216117

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500007A GT200500007A (es) 2003-08-22 2005-01-13 [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.

Country Status (36)

Country Link
US (3) US7160888B2 (es)
EP (1) EP1660497A1 (es)
JP (1) JP4034811B2 (es)
KR (2) KR100765668B1 (es)
CN (1) CN100422181C (es)
AP (1) AP2006003525A0 (es)
AR (1) AR045386A1 (es)
AU (1) AU2004266191B2 (es)
BR (1) BRPI0413860A (es)
CA (1) CA2538915C (es)
CR (2) CR8254A (es)
CU (1) CU23464B7 (es)
EA (1) EA009645B1 (es)
EC (1) ECSP066391A (es)
GE (1) GEP20084447B (es)
GT (1) GT200500007A (es)
HK (1) HK1091815A1 (es)
HN (1) HN2004000319A (es)
IL (1) IL173439A0 (es)
IS (1) IS8267A (es)
MA (1) MA28003A1 (es)
ME (1) MEP45308A (es)
MX (1) MXPA06002070A (es)
MY (1) MY140693A (es)
NL (1) NL1026892C2 (es)
NO (1) NO20060324L (es)
NZ (1) NZ545078A (es)
OA (1) OA13238A (es)
PA (1) PA8609701A1 (es)
PE (1) PE20051039A1 (es)
RS (1) RS20060129A (es)
TN (1) TNSN06063A1 (es)
TW (1) TWI298327B (es)
UA (1) UA82541C2 (es)
WO (1) WO2005019215A1 (es)
ZA (1) ZA200601526B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DK1408976T5 (da) * 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
PL1773772T3 (pl) * 2004-06-08 2010-11-30 Nsab Filial Af Neurosearch Sweden Ab Sverige Nowe dwupodstawione fenylopiperydyny/piperazyny jako modulatory neurotransmisji dopaminy
KR101245075B1 (ko) 2004-06-08 2013-03-18 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
FR2877005A1 (fr) * 2004-10-22 2006-04-28 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
EP1846411A4 (en) 2005-01-25 2010-08-04 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
WO2006090272A1 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006103559A1 (en) * 2005-04-01 2006-10-05 Warner-Lambert Company Llc Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
ES2520015T3 (es) * 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
CA2624965A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101300256A (zh) * 2005-10-31 2008-11-05 辉瑞产品公司 7-[4-(4-萘-1-基-哌嗪-1-基)-丁氧基]-3,4-二氢-1h-[1,8]萘啶-2-酮的结晶盐
JPWO2007099828A1 (ja) * 2006-02-23 2009-07-16 塩野義製薬株式会社 環式基で置換された含窒素複素環誘導体
WO2007116265A1 (en) * 2006-03-31 2007-10-18 Pfizer Products Inc. Process for making a tetrahydro-pyridoazepin-8-one compound
CA2858520A1 (en) 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
ATE514695T1 (de) * 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
US20100093738A1 (en) * 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
TW200831498A (en) * 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
WO2008084324A1 (en) * 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
AU2008254585B2 (en) * 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
PE20090759A1 (es) * 2007-05-30 2009-07-20 Wyeth Corp Derivados heteroarilo de benzodioxanos heterociclo-fusionados antidepresivos
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9505750B2 (en) 2007-12-18 2016-11-29 Actelion Pharmaceuticals Ltd. 5-aminocyclylmethyl-oxazolidin-2-one derivatives
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
CN102171197B (zh) 2008-07-31 2014-12-10 西诺米克斯公司 制备增甜剂的方法和中间体
CN102232078B (zh) 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
MA33053B1 (fr) * 2009-01-23 2012-02-01 Tadeka Pharmaceutical Company Ltd Inhibiteurs de la poly(adp-ribose) polymerase (parp)
JP5337259B2 (ja) * 2009-02-26 2013-11-06 レビバ ファーマシューティカルズ，インコーポレーテッド アリールピペラジン誘導体の組成物、合成および利用方法
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8536328B2 (en) 2010-05-04 2013-09-17 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623889B2 (en) 2010-12-17 2014-01-07 Genentech, Inc. Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
RU2627469C2 (ru) 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
ES2715562T3 (es) 2011-12-15 2019-06-04 Alkermes Pharma Ireland Ltd Profármacos de compuestos de amina secundaria
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP2827866B1 (en) 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
CN104785295B (zh) * 2015-03-18 2018-03-06 杭州创培信息科技有限公司 一种高选择性多巴胺铂炭催化剂的制备方法
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MX2021001091A (es) 2015-12-10 2022-04-26 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
CN106242934A (zh) * 2016-07-26 2016-12-21 云南民族大学 一种酮的β‑位C‑H键乙酰氧化合成方法
MX2019014514A (es) * 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
EP4434990A1 (en) 2018-06-27 2024-09-25 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
SG11202100846YA (en) 2018-08-07 2021-02-25 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
KR20210045992A (ko) * 2018-08-13 2021-04-27 에프. 호프만-라 로슈 아게 모노아실글리세롤 리파제 저해제로서의 신규 헤테로시클릭 화합물
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
PE20220565A1 (es) 2019-09-12 2022-04-13 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114634479A (zh) * 2020-12-16 2022-06-17 北京盈科瑞创新药物研究有限公司 一种派嗪衍生物、其制备方法及应用
US20240217977A1 (en) * 2021-03-31 2024-07-04 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023186023A1 (zh) * 2022-03-30 2023-10-05 苏州旺山旺水生物医药股份有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途
CN114805081B (zh) * 2022-05-20 2024-09-24 都创(上海)医药开发有限公司 一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPH07165720A (ja) * 1988-10-31 1995-06-27 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5153206A (en) 1988-12-02 1992-10-06 Pfizer Inc. Arylpiperidine derivatives
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
WO1994013643A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
EP0674631B1 (en) 1992-12-17 1999-12-08 Pfizer Inc. Substituted pyrazoles as crf antagonists
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
FR2699918B1 (fr) * 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr) 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP0839144B1 (en) 1995-07-13 2001-09-19 Knoll GmbH Piperazine derivatives as therapeutic agents
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja) 1996-03-08 1997-09-16 Nippon Shinyaku Co Ltd 医 薬
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
FR2761071B1 (fr) 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr) 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en) 1998-05-01 2001-07-31 Benz Research And Development Corporation Intraocular lens and haptics made of a copolymer
WO2001046177A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Benzofuran derivatives
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
WO2002048105A2 (en) 2000-11-16 2002-06-20 Wyeth Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EP1399438B1 (en) 2001-06-29 2005-12-07 H. Lundbeck A/S Novel heteroaryl derivatives, their preparation and use
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
HK1091815A1 (en) 2007-01-26
JP4034811B2 (ja) 2008-01-16
CN100422181C (zh) 2008-10-01
OA13238A (en) 2006-12-13
AP2006003525A0 (en) 2006-02-28
MEP45308A (en) 2011-02-10
NO20060324L (no) 2006-05-18
IL173439A0 (en) 2006-06-11
KR100765668B1 (ko) 2007-10-10
NL1026892A1 (nl) 2005-02-28
WO2005019215A1 (en) 2005-03-03
TNSN06063A1 (en) 2007-10-03
MA28003A1 (fr) 2006-07-03
US20050043309A1 (en) 2005-02-24
CU23464B7 (es) 2009-12-17
CR9834A (es) 2008-04-21
TW200524938A (en) 2005-08-01
KR20060071404A (ko) 2006-06-26
IS8267A (is) 2006-01-26
CN1839134A (zh) 2006-09-27
CA2538915C (en) 2010-06-15
ECSP066391A (es) 2006-08-30
JP2007503386A (ja) 2007-02-22
AU2004266191B2 (en) 2009-11-26
UA82541C2 (uk) 2008-04-25
EA200600294A1 (ru) 2006-08-25
EP1660497A1 (en) 2006-05-31
KR20070053364A (ko) 2007-05-23
MY140693A (en) 2010-01-15
PA8609701A1 (es) 2005-05-24
AU2004266191A1 (en) 2005-03-03
US7160888B2 (en) 2007-01-09
RS20060129A (en) 2008-06-05
TWI298327B (en) 2008-07-01
BRPI0413860A (pt) 2006-10-24
HN2004000319A (es) 2010-06-09
MXPA06002070A (es) 2006-05-19
NZ545078A (en) 2009-09-25
CA2538915A1 (en) 2005-03-03
AR045386A1 (es) 2005-10-26
KR100801794B1 (ko) 2008-02-05
GEP20084447B (en) 2008-08-10
US20060287309A1 (en) 2006-12-21
CR8254A (es) 2006-10-17
ZA200601526B (en) 2007-04-25
US20060287310A1 (en) 2006-12-21
PE20051039A1 (es) 2005-12-12
EA009645B1 (ru) 2008-02-28
NL1026892C2 (nl) 2005-11-21

Similar Documents

Publication Publication Date Title
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
UY28348A1 (es) Compuestos novedosos
UY28342A1 (es) Nuevos compuestos
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY28572A1 (es) Compuestos novedosos
UY28510A1 (es) Compuestos quimicos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
AR048912A1 (es) Inmunoglobulinas anti-nogo
AR028948A1 (es) Compuestos novedosos
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
CR7069A (es) Derivados de pirazol para el tratamiento de vih
HN2001000006A (es) Antagonistas del factor liberador de corticotropina
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY27894A1 (es) Derivados de cinamida.
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
PA8452701A1 (es) Agonistas de prostaglandinas
GT200600130A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
UY27394A1 (es) Pedidos con actividad anti- angiogéna.